Immunization

Analysis shows that the ratio of neutralizing antibody geometric mean titers in adolescents compared with young adults was 1.5 after vaccination with NVX-CoV2373.

Prevnar 20 is a next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes already included in Prevnar 13.

The analysis, published in Nature Communications, demonstrates glycan trimming also keeps the antibody response away from immunodominant glucan holes and patches.

Study results indicate a decrease in the exclusion of older adults but no significant change for individuals who are immunocompromised.

A 10% increase in the proportion of adults aged 50 years or older was associated with a 1.2% increase in pneumococcal vaccination coverage.

VAX-24 is designed to prevent invasive pneumococcal disease and pneumonia, which can be most serious for infants, young children, older adults, and those with immune deficiencies or some chronic health conditions.

Building strong, trusting relationships helps combat hesitancy, creating healthier communities.

Agency updates emergency use authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccinations, which are no longer authorized for used in the United States.

Atypical respiratory syncytial virus epidemics may continue, and testing patients for multiple respiratory pathogens when indicated might be necessary.

Respiratory syncytial virus (RSV) vaccine demonstrated efficacy of 66.7% in reducing RSV-associated lower respiratory tract illness with at least 2 signs or symptoms in older adults.

The trial did not meet the second primary efficacy endpoint of medically attended respiratory syncytial virus-associated lower respiratory tract illness.

Not only are pharmacists easily accessible to the public, they are also highly visible as a source for travel immunization services.

The patient had no significant past medical complications and was fully immunized for the age-based recommendation from the Advisory Council and Immunization Practices, study shows.

Among those without HIV, the analyses found that respondents with a history of COVID-19 performed worse on processing speed than those who had never had COVID-19.

Investigators analyze to see if there was an association of expected benefits and risk of vaccination.

The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021.

Imminent March, April expiration dates indicate changes are on the horizon for pharmacy services.

Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, discusses current outlook on the occurrence of outbreaks of vaccine-preventable diseases in the country.

Services include adherence assessments, health screenings, medication reconciliation, vaccine administration.

Investigators estimate that the effectiveness was higher after 1 or 2 booster doses compared with the primary series alone.

Findings from the ongoing Adult Respiratory Syncytial Virus phase 3 trial suggest RSVPreF3 OA vaccine is effective and safe for individuals aged 60 years and older.

Further research is needed across countries and health systems about PCV13, according to the systematic review published in Taylor & Francis Online.

Staff members, especially immunizers, should look at every encounter as an opportunity to educate, support patients.

MenABCWY combination meets all 11 primary endpoints and shows that it is well tolerated, with a safety profile consistent with MenACWY (Menveo) and MenB (Bexsero).

Among the participants who were initially unsure or hesitant about vaccination, 82% received flu and Tdap vaccines during pregnancy after the online intervention.

This episode features Bruce Berger, PhD, president of Berger Consulting, LLC, who discusses how pharmacists should best use motivational interviewing with patients.

The fourth dose of the bivalent vaccine elicited improved Omicron BA.4/BA.5-neutralizing antibody responses compared to participants who received 3 doses of the original vaccine.

Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.

Due to the success of mRNA technology with COVID-19, there has been a significant increase in research looking into utilizing mRNA technology, and more specifically, how it can help to advance vaccine development.

The FDA set a Prescription Drug User Fee Act for May 2023 for Pfizer’s respiratory syncytial virus bivalent vaccine candidate.